Pharming Group N.V.
PHARM.AS · AMS
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €286,887 | €245,316 | €205,622 | €189,853 |
| % Growth | 16.9% | 19.3% | 8.3% | – |
| Cost of Goods Sold | €42,934 | €25,212 | €17,562 | €20,183 |
| Gross Profit | €231,821 | €220,104 | €188,060 | €169,670 |
| % Margin | 80.8% | 89.7% | 91.5% | 89.4% |
| R&D Expenses | €73,367 | €68,914 | €52,531 | €67,178 |
| G&A Expenses | €92,081 | €80,684 | €46,016 | €35,297 |
| SG&A Expenses | €161,843 | €87,501 | €131,819 | €92,047 |
| Sales & Mktg Exp. | €7,135 | €6,817 | €85,803 | €56,750 |
| Other Operating Expenses | €0 | €69,076 | -€14,523 | -€2,502 |
| Operating Expenses | €235,210 | €225,491 | €169,827 | €156,723 |
| Operating Income | -€3,388 | -€4,880 | €18,233 | €27,839 |
| % Margin | -1.2% | -2% | 8.9% | 14.7% |
| Other Income/Exp. Net | -€4,462 | -€7,132 | -€3,246 | -€4,761 |
| Pre-Tax Income | -€7,851 | -€12,012 | €14,987 | €22,032 |
| Tax Expense | €2,427 | -€1,464 | €1,313 | €6,760 |
| Net Income | -€10,644 | -€10,548 | €13,674 | €15,996 |
| % Margin | -3.7% | -4.3% | 6.7% | 8.4% |
| EPS | -0.015 | -0.013 | 0.017 | 0.02 |
| % Growth | -20.3% | -176.2% | -16% | – |
| EPS Diluted | -0.015 | -0.013 | 0.015 | 0.018 |
| Weighted Avg Shares Out | 689,187 | 821,276 | 883,927 | 876,439 |
| Weighted Avg Shares Out Dil | 689,188 | 843,250 | 883,927 | 876,439 |
| Supplemental Information | – | – | – | – |
| Interest Income | €5,721 | €3,529 | €81 | €14,230 |
| Interest Expense | €8,737 | €5,964 | €5,198 | €5,916 |
| Depreciation & Amortization | €10,208 | €15,925 | €13,188 | €19,610 |
| EBITDA | €13,178 | €9,877 | €33,533 | €48,779 |
| % Margin | 4.6% | 4% | 16.3% | 25.7% |